Efficacy of different pharmaceutical forms of Curcuma longa or curcumin in reducing oral mucositis severity and incidence in cancer patients: a systematic review and meta-analysis DOI Creative Commons
Pedro de Padua G. Amatto, Lucas Chaves, Suzelei de Castro França

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: April 2, 2025

Curcuma longa L. (turmeric, Zingiberaceae) has been traditionally used for its anti-inflammatory, wound-healing, and antimicrobial properties. These characteristics have made it a key component in managing inflammatory ulcerative conditions like oral mucositis (OM). This study aimed to evaluate the effectiveness of various pharmaceutical formulations C. or curcumin reducing OM severity, incidence associated pain patients undergoing chemotherapy and/or radiotherapy cancer. systematic review meta-analysis randomized clinical trials was conducted according PRISMA guidelines, registered PROSPERO (#CRD42024504111). Searches were performed PubMed, Embase, Cochrane databases. Studies comparing with placebo cancer experiencing mucositis, reporting outcomes such as World Health Organization Oral Mucositis Grading Scale, scores (visual analogue scale), included. Risk ratios weighted mean differences 95% confidence intervals calculated using fixed- random-effects models. Six studies 159 (mean age ∼50 years, 40% women) extracts, curcumin, nanocurcumin administered capsules, mouthwash, gel formulations. The pooled analysis showed significant reductions WHO compared placebo. decreased by 6% overall, notable 37%-reduction observed curcumin-containing mouthwash during alone. Subgroup analyses revealed consistent benefits across all oncological treatments. longa, formulations, effectively reduce severity while reduced treatment. identifier CRD 42024504111.

Language: Английский

Evaluation of Preclinical Efficacy of Curcumin-Loaded Bicosome Systems in Amelioration of Oral Mucositis DOI Creative Commons
Daniela Vergara, Claudia Sanhueza,

Susana Méndez

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(2), P. 181 - 181

Published: Feb. 1, 2025

Background/Objectives: Oral mucositis (OM) is a common and debilitating side effect of cancer therapy, characterized by ulceration or inflammation the oral mucosa. This study evaluates preclinical efficacy curcumin-loaded bicosome systems (cur-BS) in mitigating chemotherapy-induced OM mice. Methods: BS were prepared using combination 1,2-di-palmitoyl-sn-glycero-3-phosphocholine (DPPC) 1,2-dihexanoyl-sn-glycero-3-phosphocholine (DHPC), α-tocopherol, curcumin, encapsulated within liposomal vesicles. Three formulations with different curcumin concentrations (180, 540, 900 μM) particle size, polydispersity index (PDI), encapsulation efficiency (EE), appearance, morphology. The formulation highest concentration (cur-BS 5×) was selected for ex vivo permeability studies, release profile analysis, vitro anti-inflammatory efficacy. induced mice 5-fluorouracil (5-FU) acetic acid. Cur-BS 5× compared to commercial product Dentoxol®. Results: results showed that cur-BS provided sustained through mechanism involving both diffusion matrix relaxation, enhancing retention deeper skin layers. Treatment downregulated expression inflammatory markers (IL-1β TNF-α). Macroscopic assessments demonstrated Dentoxol® reduced severity, greatest improvement observed between days 6 9. By day 24, scores 1.25 ± 0.5 1.0 0.0 Dentoxol®, indicating effectiveness treatments. However, histological analysis revealed superior tissue recovery 5×, showing better epithelial structure inflammation. 5×-treated also exhibited greater weight higher survival rates group. Conclusions: These findings suggest may enhance treatment, offering outcomes comparable than those

Language: Английский

Citations

0
Sublethal Curcumin Exposure Induces Global Gene Expression and Biofilm-Related Phenotypic Changes in Vibrio parahaemolyticus DOI

Lili Huang,

Miaomiao Zhang, Xi Luo

et al.

Current Microbiology, Journal Year: 2025, Volume and Issue: 82(5)

Published: March 26, 2025

Language: Английский

Citations

0
Efficacy of different pharmaceutical forms of Curcuma longa or curcumin in reducing oral mucositis severity and incidence in cancer patients: a systematic review and meta-analysis DOI Creative Commons
Pedro de Padua G. Amatto, Lucas Chaves, Suzelei de Castro França

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: April 2, 2025

Curcuma longa L. (turmeric, Zingiberaceae) has been traditionally used for its anti-inflammatory, wound-healing, and antimicrobial properties. These characteristics have made it a key component in managing inflammatory ulcerative conditions like oral mucositis (OM). This study aimed to evaluate the effectiveness of various pharmaceutical formulations C. or curcumin reducing OM severity, incidence associated pain patients undergoing chemotherapy and/or radiotherapy cancer. systematic review meta-analysis randomized clinical trials was conducted according PRISMA guidelines, registered PROSPERO (#CRD42024504111). Searches were performed PubMed, Embase, Cochrane databases. Studies comparing with placebo cancer experiencing mucositis, reporting outcomes such as World Health Organization Oral Mucositis Grading Scale, scores (visual analogue scale), included. Risk ratios weighted mean differences 95% confidence intervals calculated using fixed- random-effects models. Six studies 159 (mean age ∼50 years, 40% women) extracts, curcumin, nanocurcumin administered capsules, mouthwash, gel formulations. The pooled analysis showed significant reductions WHO compared placebo. decreased by 6% overall, notable 37%-reduction observed curcumin-containing mouthwash during alone. Subgroup analyses revealed consistent benefits across all oncological treatments. longa, formulations, effectively reduce severity while reduced treatment. identifier CRD 42024504111.

Language: Английский

Citations

0